Rubicon Research targets Rs 500 crore R&D after 3.3x-5.9x

Rubicon Research is targeting more than Rs 500 crore of research and development spending across FY26, FY27 and Q1 FY28 after its four reported R&D productivity cycles produced multiples of 3.3x to 5.9x. The company had spent Rs 313.9 crore in the first six quarters and says the programme supports visibility for FY29, FY30 and beyond.

How does Rubicon Research calculate R&D productivity?

Rubicon Research calculates R&D productivity as incremental revenue in year three divided by total R&D spending over the preceding nine quarters. The company says this nine-quarter lag reflects the typical time required for R&D expenditure to translate into revenue, including product development, regulatory processes and commercialisation.

The metric differs from the accounting treatment of R&D. Rubicon Research charges all R&D expenditure to the profit and loss account in the period incurred, but combines spending across a nine-quarter cycle for its productivity measure. For example, the FY26 cycle includes spending in FY25, FY26 and Q1 FY27 totalling Rs 384.1 crore, rather than R&D expense recorded in FY26 alone.

Rubicon Research uses product sales as the base for its calculation. Base-year product sales rose from Rs 299.9 crore in FY21 to Rs 839.8 crore in FY24, while impact-year product sales were Rs 839.8 crore in FY24 and Rs 2,105.6 crore in FY27. The company measures incremental revenue against these base-year sales levels.

What has Rubicon Research spent on R&D?

Rubicon Research recorded R&D expense of Rs 120.4 crore in H1 FY27, equal to 10.8% of consolidated operating revenue. This followed Rs 132.5 crore, or 10.3% of operating revenue, in FY25 and Rs 193.5 crore, or 11.0%, in FY26, placing the expense ratio within the 10% to 11% range cited by the company for those two years.

FY22 was materially different from the later years. Rubicon Research spent Rs 124 crore on R&D in FY22, representing 39.5% of operating revenue, and reported a post-R&D operating earnings before interest, tax, depreciation and amortisation, or EBITDA, margin of negative 12.5%. In FY23, R&D expense fell to Rs 70.9 crore, or 18.0% of operating revenue, and the post-R&D operating EBITDA margin turned positive at 4.7%.

The increase from Rs 132.5 crore in FY25 to Rs 193.5 crore in FY26 was accompanied by a 0.7-percentage-point rise in the R&D-to-revenue ratio, from 10.3% to 11.0%. H1 FY27 expense of Rs 120.4 crore covers six months, while the Rs 313.9 crore disclosed for the new nine-quarter programme covers the first six quarters of that separate productivity cycle.

What do Rubicon Research's past R&D cycles show?

Rubicon Research reported productivity of 3.3x, 4.1x, 5.9x and 5.8x for the FY21 through FY24 cycles, respectively, using its incremental-revenue-to-lagged-spend calculation. The highest reported multiple was 5.9x for the FY23 cycle, which paired Rs 226.1 crore of nine-quarter R&D spend with Rs 1,345.8 crore of incremental revenue.

The FY24 figure of 5.8x is not based on reported full-year FY27 sales. Rubicon Research says it uses arithmetic annualisation of H1 FY27 revenue excluding Arinna, and that the multiple will expand further if revenue increases during the remaining FY27 quarters. The figure should therefore be treated differently from the prior completed-cycle results.

The series also shows that the spending level and reported productivity did not move in parallel. Nine-quarter spending declined from Rs 237.9 crore in the FY22 cycle to Rs 218.7 crore in FY24, while productivity rose from 4.1x to 5.8x. Incremental revenue in the FY24 cycle, at Rs 1,265.7 crore, was below the Rs 1,345.8 crore reported for FY23 despite the higher stated productivity multiple.

What does the FY26-to-Q1 FY28 R&D plan indicate?

Rubicon Research is on track, according to its presentation, to spend more than Rs 500 crore over FY26, FY27 and Q1 FY28. It had spent Rs 313.9 crore over the first six quarters, leaving FY27 H2 and Q1 FY28 as the remaining three quarters in the nine-quarter programme.

The planned cycle exceeds the Rs 384.1 crore of spending in the preceding FY26 productivity cycle and the Rs 275.2 crore in the FY25 cycle. Rubicon Research also says FY27 has the lowest absolute lagging R&D spend among the latest three cycles, which it identifies as a factor affecting the FY27 revenue-impact period under its methodology.

Management says productivity at levels similar to the historical 3.3x to 5.9x range would provide visibility for FY29, FY30 and beyond. The presentation does not give a revenue target from the more than Rs 500 crore programme, and it does not specify product-level revenue contributions. Conversion will depend on the R&D pipeline progressing through approvals and commercialisation over the company’s stated timeline.

Conclusion

Rubicon Research's disclosure sets out a defined, company-specific link between R&D expenditure and later product revenue. R&D expense returned to 10.3% to 11.0% of operating revenue in FY25 and FY26 after the FY22 spending peak, while its reported historical productivity range was 3.3x to 5.9x across four cycles.

The next milestones are completion of the nine-quarter programme through Q1 FY28 after Rs 313.9 crore of spending in its first six quarters, and reported FY27 revenue that will replace the annualised basis of the provisional 5.8x FY24-cycle calculation. Management's FY29 and FY30 visibility depends on productivity remaining similar to past cycles, rather than on a disclosed revenue target.